Relay Therapeutics Ownership | Who Owns Relay Therapeutics?
Relay Therapeutics Ownership Summary
Relay Therapeutics is owned by 12.68% institutional investors, 1.51% insiders, and 85.81% retail investors. Sb investment advisers (uk) is the largest institutional shareholder, holding 16.29% of RLAY shares. BB Biotech AG Ord is the top mutual fund, with 4.41% of its assets in Relay Therapeutics shares.
RLAY Ownership Benchmark
Type | Name | % Inst | % Insiders | % Retail |
---|---|---|---|---|
Stock | Relay Therapeutics | 12.68% | 1.51% | 85.81% |
Sector | Healthcare Stocks | 279.42% | 10.64% | -190.05% |
Industry | Biotech Stocks | 64.05% | 10.69% | 25.27% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
Holder | Shares | % Holding | Value |
---|---|---|---|
Sb investment advisers (uk) | 27.90M | 16.29% | $96.55M |
Vanguard group | 15.03M | 10.72% | $61.92M |
Blackrock funding, inc. /de | 13.95M | 8.15% | $48.28M |
Blackrock | 10.54M | 7.94% | $68.74M |
Point72 asset management | 13.45M | 7.85% | $46.52M |
Casdin capital | 11.40M | 6.66% | $39.44M |
Bellevue group | 8.23M | 4.81% | $28.48M |
Tang capital management | 8.07M | 4.71% | $27.92M |
Norges bank | 5.78M | 4.12% | $23.82M |
Jpmorgan chase | 4.98M | 3.55% | $20.51M |
Top Institutional Shareholders by % of Total Assets
Holder | Shares | % Assets | Value |
---|---|---|---|
Casdin capital | 11.40M | 3.59% | $39.44M |
Foresite capital management iv | 1.00M | 2.79% | $3.46M |
Nextech invest | 3.85M | 2.57% | $15.85M |
Tang capital management | 8.07M | 1.41% | $27.92M |
Bioimpact capital | 2.28M | 1.37% | $7.90M |
Harbourvest partners | 296.40K | 1.12% | $1.03M |
Kynam capital management, lp | 2.89M | 1.08% | $9.99M |
Sb investment advisers (uk) | 27.90M | 0.77% | $96.55M |
Bellevue group | 8.23M | 0.63% | $28.48M |
Boxer capital | 1.82M | 0.62% | $11.86M |
Top Buyers
Holder | Shares | % Assets | Change |
---|---|---|---|
Norges bank | 5.78M | 0.00% | 5.78M |
Point72 asset management | 13.45M | 0.09% | 2.62M |
Casdin capital | 11.40M | 3.59% | 2.30M |
Dimensional fund advisors lp | 2.96M | 0.00% | 1.22M |
Renaissance | 1.55M | 0.01% | 878.10K |
Top Sellers
Holder | Shares | % Assets | Change |
---|---|---|---|
Braidwell lp | - | - | -3.50M |
Eventide asset management | - | - | -2.68M |
Finepoint capital lp | - | - | -2.12M |
Price t rowe associates inc /md/ | 3.32M | 0.00% | -1.96M |
State street | 4.25M | 0.00% | -1.77M |
New Positions
Holder | Shares | % Assets | Change | Value |
---|---|---|---|---|
Norges bank | 5.78M | 0.00% | 5.78M | $23.82M |
Tfg asset management gp | 619.00K | 0.37% | 619.00K | $1.62M |
Eversept partners, lp | 533.41K | 0.17% | 533.41K | $1.85M |
Bnp paribas arbitrage, snc | 239.67K | 0.00% | 239.67K | $987.43K |
Susquehanna portfolio strategies | 238.81K | 0.02% | 238.81K | $826.30K |
Sold Out
Holder | Change |
---|---|
Tfc financial management | -1.00 |
Capital performance advisors llp | -11.00 |
Parallel advisors | -14.00 |
Nelson, van denburg & campbell wealth management group | -18.00 |
First command advisory services | -25.00 |
Institutional Ownership Trends
Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
---|---|---|---|---|---|---|---|---|---|---|
Mar 31, 2025 | 13 | -93.60% | 21,465,711 | -86.91% | 12 | 0.09% | 8 | -93.89% | 2 | -94.44% |
Dec 31, 2024 | 192 | -3.52% | 130,207,976 | -17.33% | 92 | 0.74% | 123 | 4.24% | 35 | -22.22% |
Sep 30, 2024 | 198 | 11.24% | 157,463,305 | 24.21% | 112 | 1.23% | 118 | 20.41% | 45 | -6.25% |
Jun 30, 2024 | 178 | -4.30% | 126,768,728 | -1.54% | 95 | 0.99% | 98 | -3.92% | 48 | - |
Mar 31, 2024 | 186 | 5.68% | 128,755,897 | 1.37% | 98 | 0.92% | 102 | 18.60% | 48 | -17.24% |
Top Mutual Funds Shareholders
Holder | Shares | % Holding | Change |
---|---|---|---|
BB Biotech AG Ord | 7.38M | 4.41% | - |
Vanguard Total Stock Mkt Idx Inv | 5.17M | 3.01% | -114.66K |
Vanguard US Total Market Shares ETF | 4.89M | 2.88% | 904.00K |
iShares Russell 2000 ETF | 3.16M | 1.84% | -60.06K |
Eventide Healthcare & Life Sciences I | 2.68M | 1.56% | - |
JPMorgan Small Cap Growth A | 2.20M | 1.29% | 32.86K |
SPDR® S&P Biotech ETF | 2.20M | 1.29% | 54.45K |
Vanguard Small Cap Index | 2.02M | 1.18% | 7.50K |
Belfius Equities Cure C Cap | 1.73M | 1.02% | - |
Vanguard Institutional Extnd Mkt Idx Tr | 1.43M | 0.84% | -620.47K |
Recent Insider Transactions
Date | Name | Role | Activity | Value |
---|---|---|---|---|
Jul 29, 2025 | Rahmer Peter | See remarks | Sell | $57.86K |
Jul 28, 2025 | Rahmer Peter | See remarks | Sell | $5.08K |
Jul 28, 2025 | Catinazzo Thomas | Chief Financial Officer | Sell | $6.36K |
Jul 29, 2025 | Catinazzo Thomas | Chief Financial Officer | Sell | $67.64K |
Jul 28, 2025 | Bergstrom Donald A | President, R&D | Sell | $15.22K |
Insider Transactions Trends
Date | Buy | Sell |
---|---|---|
2025 Q3 | - | 10 |
2025 Q2 | - | 12 |
2025 Q1 | - | 25 |
2024 Q4 | - | 12 |
2024 Q3 | - | 15 |
RLAY Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools